Build back better: Advances in tuberculosis research in Canada & globally in 2020

References

• WHO. Global Tuberculosis Report: 2020. Geneva: World Health Organization, 2020.
   Google Scholar
• Basham CA, Elias B, Orr P. Tuberculosis elimination in Canada. The Lancet. 2019;394(10195):300–301. doi:10.1016/S0140-6736(19)31122-5.
   Web of Science ®Google Scholar
• Public Health Agency of Canada. Canadian Tuberculosis Standards. 7th ed. Ottawa (ON): Government of Canada, 2014.
   Google Scholar
• LaFreniere M, Hussain H, He N, McGuire M. Tuberculosis in Canada: 2017. Can Commun Dis Rep. 2019;45(2-3):67–73. doi:10.14745/ccdr.v45i23a04.
   PubMedGoogle Scholar
• Alvarez GG, Zwerling AA, Duncan C, et al. Molecular epidemiology of Mycobacterium tuberculosis to describe the transmission dynamics among Inuit residing in Iqaluit Nunavut using whole genome sequencing. Clin Infect Dis. 2020; published online April 13.
   Google Scholar
• Alvarez GG, Van Dyk D, Mallick R, et al. The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study. Int J Circumpolar Health. 2020;79(1):1758501.
   Web of Science ®Google Scholar
• Menzies NA, Bellerose M, Testa C, et al. Impact of Effective Global Tuberculosis Control on Health and Economic Outcomes in the United States. Am J Respir Crit Care Med. 2020;202(11):1567–1575. published online July 9. doi:10.1164/rccm.202003-0526OC.
   Web of Science ®Google Scholar
• WHO. Global Tuberculosis Report: 2018. Geneva: World Health Organization, 2019.
   Google Scholar
• WHO. Global Tuberculosis Report: 2019. Geneva: World Health Organization, 2019.
   Google Scholar
• Long R, King M, Doroshenko A, Heffernan C. Tuberculosis and COVID-19 in Canada. EClinicalMedicine. 2020;27:100584. doi:10.1016/j.eclinm.2020.100584.
   Google Scholar
• Cilloni L, Fu H, Vesga JF, et al. The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis. EClinicalMedicine. 2020;28:100603. doi:10.1016/j.eclinm.2020.100603.
   PubMedGoogle Scholar
• Saroufim M, Geric C, Mannix S, et al. Impact of COVID-19 pandemic on latent and active tuberculosis treatment registrations in Montreal, Canada: a retrospective study at the Montreal Chest Institute. International Journal of Tuberculosis and Lung Disease. 2020; 24:S396.
   Google Scholar
• Zumla A, Marais BJ, McHugh TD, et al. COVID-19 and tuberculosis-threats and opportunities. Int J Tuberc Lung Dis. 2020;24(8):757–760. doi:10.5588/ijtld.20.0387.
   Web of Science ®Google Scholar
• Murphy K, Habib SS, Zaidi SMA, et al. Computer aided detection of tuberculosis on chest radiographs: An evaluation of the CAD4TB v6 system. Sci Rep. 2020;10(1):5492. doi:10.1038/s41598-020-62148-y.
   PubMed Web of Science ®Google Scholar
• WHO. Rapid Communication on Systematic Screening for Tuberculosis. Geneva: World Health Organization, 2020.
   Google Scholar
• Khan FA, Majidulla A, Tavaziva G, et al. Chest x-ray analysis with deep learning-based software as a triage test for pulmonary tuberculosis: a prospective study of diagnostic accuracy for culture-confirmed disease. The Lancet Digital Health. 2020;2(11):e573–81–e581. doi:10.1016/S2589-7500(20)30221-1.
   Google Scholar
• Wang W-H, Takeuchi R, Jain S-H, et al. A novel, rapid (within hours) culture-free diagnostic method for detecting live Mycobacterium tuberculosis with high sensitivity. EBioMedicine. 2020;60:103007. doi:10.1016/j.ebiom.2020.103007.
   Web of Science ®Google Scholar
• Campbell JR, Winters N, Menzies D. Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis. BMJ. 2020; 368:m549 doi:10.1136/bmj.m549.
   PubMedGoogle Scholar
• Zhou G, Luo Q, Luo S, et al. Interferon-γ release assays or tuberculin skin test for detection and management of latent tuberculosis infection: a systematic review and meta-analysis. The Lancet Infectious Diseases. 2020;20(12):1457–1469. doi:10.1016/S1473-3099(20)30276-0.
   Web of Science ®Google Scholar
• Oh CE, Ortiz-Brizuela E, Bastos ML, Menzies D. Comparing the diagnostic performance of QFT-plus to other tests of latent tuberculosis infection: A systematic review and meta-analysis. Clin Infect Dis. 2020; published online Dec 8.
   Google Scholar
• Esmail H, Cobelens F, Goletti D. Transcriptional biomarkers for predicting development of tuberculosis: progress and clinical considerations. Eur Respir J. 2020;55(3):1901957. doi:10.1183/13993003.01957-2019.
   PubMed Web of Science ®Google Scholar
• Mulenga H, Zauchenberger C-Z, Bunyasi EW, et al. Performance of diagnostic and predictive host blood transcriptomic signatures for Tuberculosis disease: A systematic review and meta-analysis. PLoS ONE. 2020;15(8):e0237574. doi:10.1371/journal.pone.0237574.
   PubMed Web of Science ®Google Scholar
• WHO. Framework for the Evaluation of New Tests for Tuberculosis Infection. Geneva: World Health Organization, 2020.
   Google Scholar
• Campbell JR, Al-Jahdali H, Bah B, et al. Safety and efficacy of rifampin or isoniazid among people with mycobacterium tuberculosis infection and living with HIV or other health conditions: Post-hoc analysis of two randomized trials. Clin Infect Dis. 2020; published online Aug 12.
   Google Scholar
• Yuen CM, Seddon JA, Keshavjee S, Dodd PJ. Risk-benefit analysis of tuberculosis infection testing for household contact management in high-burden countries: a mathematical modelling study. Lancet Glob Health. 2020;8(5):e672–80–e680. doi:10.1016/S2214-109X(20)30075-9.
   Web of Science ®Google Scholar
• Schmit KM, Wortham JM, Ho CS, Powell KM. Analysis of severe adverse events reported among patients receiving isoniazid-rifapentine treatment for latent mycobacterium tuberculosis infection-United States, 2012-2016. Clin Infect Dis. 2020;71(9):2502–2505. doi:10.1093/cid/ciaa286.
   Web of Science ®Google Scholar
• Menzies D. Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB (2R2). 2020. published online July 30. https://clinicaltrials.gov/ct2/show/NCT03988933. Accessed December 13, 2020.
   Google Scholar
• Centers for Disease Control and Prevention. Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI (ASTERoiD). 2020. published online Jan 30. https://clinicaltrials.gov/ct2/show/NCT03474029. Accessed December 13, 2020.
   Google Scholar
• Fox GJ, Nguyen CB, Nguyen TA, et al. Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial. BMJ Open. 2020;10(1):e033945. doi:10.1136/bmjopen-2019-033945.
   PubMed Web of Science ®Google Scholar
• WHO. Target Product Profiles for Tuberculosis Preventive Treatment. Geneva: World Health Organization, 2020.
   Google Scholar
• Menzies D, Gardiner G, Farhat M, Greenaway C, Pai M. Thinking in three dimensions: a web-based algorithm to aid the interpretation of tuberculin skin test results. Int J Tuberc Lung Dis. 2008;12(5):498–505.
   Web of Science ®Google Scholar
• Puyat JH, Shulha HP, Balshaw R, et al. How well does TSTin3D predict risk of active tuberculosis in the Canadian immigrant population? An External Validation Study. Clin Infect Dis. 2020; published online June 18.
   Google Scholar
• Gupta RK, Calderwood CJ, Yavlinsky A, et al. Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings. Nat Med. 2020;26(12):1941–1949. published online Oct 19. doi:10.1038/s41591-020-1076-0.
   PubMed Web of Science ®Google Scholar
• Oxlade O, Benedetti A, Anagonou S, et al. Enhancing the Public Health Impact of Latent Tuberculosis Infection Management: The ACT4 Cluster Randomized Trial. Lancet Public Health. 2020.
   Google Scholar
• Alsdurf H, Oxlade O, Adjobimey M, et al. Resource implications of the latent tuberculosis cascade of care: a time and motion study in five countries. BMC Health Serv Res. 2020;20(1):341. doi:10.1186/s12913-020-05220-7.
   Web of Science ®Google Scholar
• Bastos ML, Oxlade O, Benedetti A, et al. A public health approach to increase treatment of latent TB among household contacts in Brazil. Int J Tuberc Lung Dis. 2020;24(10):1000–1008. doi:10.5588/ijtld.19.0728.
   Web of Science ®Google Scholar
• Barss L, Obeng J, Fregonese F, et al. Solutions to improve the latent tuberculosis Cascade of Care in Ghana: a longitudinal impact assessment. BMC Infect Dis. 2020;20(1):352. doi:10.1186/s12879-020-05060-0.
   Web of Science ®Google Scholar
• Marais B, Zumla A. Advancing global tuberculosis control after the UNGA-HLM. Lancet. 2018;392(10153):1096–1097. doi:10.1016/S0140-6736(18)32361-4.
   PubMed Web of Science ®Google Scholar
• Basham CA, Cook VJ, Johnston JC. Towards a ‘fourth 90’: A population-based analysis of post-tuberculosis pulmonary function testing in British Columbia, Canada, 1985-2015. Eur Respir J. 2020;56(2):2000384. published online April 7. doi:10.1183/13993003.00384-2020.
   Web of Science ®Google Scholar
• Basham CA, Karim ME, Cook VJ, Patrick DM, Johnston JC. Post-tuberculosis mortality risk among immigrants to British Columbia, Canada, 1985-2015: a time-dependent Cox regression analysis of linked immigration, public health, and vital statistics data. Can J Public Health. 2021;112(1):132–141.
   Web of Science ®Google Scholar
• Quaife M, Houben RMGJ, Allwood B, et al. Post-tuberculosis mortality and morbidity: valuing the hidden epidemic. Lancet Respir Med. 2020;8(4):332–333. https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30039-4/abstract. doi:10.1016/S2213-2600(20)30039-4.
   PubMed Web of Science ®Google Scholar
• Dorman S, Kurbatova E, Nahid P, Muzayne G, Chaisson R. High-dose rifapentine with or without moxifloxacin for shortening treatment of TB: TB Trials Consortium study 31/ACTG A5349 phase III clinical trial results. Paper presented at: The 51st Union World Conference on Lung Health. 2020;112(1):132–141.
   Google Scholar
• Imperial MZ, Nahid P, Phillips PPJ, et al. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nat Med. 2018;24(11):1708–1715. doi:10.1038/s41591-018-0224-2.
   PubMed Web of Science ®Google Scholar
• WHO. WHO Consolidated Guidelines on Tuberculosis. Module 4, Treatment: Drug-Resistant Tuberculosis Treatment. Geneva: World Health Organization, 2020. https://www.who.int/publications/i/item/9789240007048 (accessed July 31, 2020).
   Google Scholar
• Conradie F, Diacon AH, Ngubane N, Nix-TB Trial Team, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893–902. doi:10.1056/NEJMoa1901814.
   PubMed Web of Science ®Google Scholar
• Global Alliance for TB Drug Development. Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant MDR-TB (ZeNix). 2020. published online Jan 9. https://clinicaltrials.gov/ct2/show/NCT03086486. Accessed December 13, 2020.
   Google Scholar
• Government of Canada, Health Canada. Update on the rifampin drug shortage. 2020; published online March 13. https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/72601a-eng.php. Accessed December 15, 2020.
   Google Scholar
• Centers for Disease Control and Prevention. Reported Rifapentine Impurity. 2020. published online June 23. https://www.cdc.gov/tb/publications/letters/reported_rifapentine.html. Accessed December 15, 2020.
   Google Scholar
• Nash M, Perrin C, Seddon JA, et al. Access to paediatric formulations for the treatment of childhood tuberculosis. Lancet Child Adolesc Health. 2020;4(12):855–857. doi:10.1016/S2352-4642(20)30273-X.
   PubMedGoogle Scholar
• Houston AR, Cooper R, Khan FA. Responsible use of rifampin in Canada is threatened by irresponsible shortages. CMAJ. 2019;191(41):E1139. doi:10.1503/cmaj.73160.
   Web of Science ®Google Scholar